Extracellular vesicle drug delivery system, preparation method thereof and application of extracellular vesicle drug delivery system in treatment of Alzheimer's disease

By regulating the expression of extracellular vesicle miRNA, an extracellular vesicle drug delivery system with active therapeutic capabilities was prepared, solving the problems of penetration ability and enrichment of extracellular vesicles in the treatment of Alzheimer's disease, and achieving effective brain drug delivery and therapeutic effects.

CN121825870APending Publication Date: 2026-04-10CAPITAL UNIVERSITY OF MEDICAL SCIENCES
0 Cites 2 Cited by

Patent Information

Application Number
CN202610048915.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-14
Publication Date
2026-04-10

AI Technical Summary

Technical Problem

In the existing technology, extracellular vesicles as drug delivery carriers have limited ability to penetrate the blood-brain barrier, short half-life in the blood, low accumulation at lesion sites, and insufficient abundance of therapeutic bioactive substances, which limit their application potential in the treatment of Alzheimer's disease.

Method used

By regulating the expression of miRNAs in extracellular vesicles, and using compounds such as stilbene glycosides, emodin, kaempferol, resveratrol, and quercetin, we can significantly upregulate miRNAs that negatively regulate disease progression and downregulate miRNAs that positively regulate disease progression, thus preparing an extracellular vesicle drug delivery system with active therapeutic capabilities.

Benefits of technology

It improves drug accumulation and retention in extracellular vesicles in the brain, enhances therapeutic effects, and alleviates Alzheimer's disease symptoms, including reducing abnormal phosphorylation of Tau protein, inhibiting microglia activation, and protecting neurons.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.
Need to check novelty before this filing date? Find Prior Art